These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7028793)
21. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Kenny JB; Wilkinson PM Clin Oncol; 1982 Dec; 8(4):335-9. PubMed ID: 7168926 [No Abstract] [Full Text] [Related]
22. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Einhorn LH; Nagy C; Furnas B; Williams SD J Clin Pharmacol; 1981; 21(S1):64S-69S. PubMed ID: 6271844 [TBL] [Abstract][Full Text] [Related]
23. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994 [TBL] [Abstract][Full Text] [Related]
25. [Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's transl) clinical studies]. Higi M; Niederle N; Bremer K; Schmitt G; Schmidt CG; Seeber S Dtsch Med Wochenschr; 1982 Aug; 107(33):1232-4. PubMed ID: 7049655 [No Abstract] [Full Text] [Related]
26. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464 [TBL] [Abstract][Full Text] [Related]
27. Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy. Joss RA; Galeazzi RL; Bischoff AK; Brunner KW Eur J Clin Pharmacol; 1985; 27(6):721-5. PubMed ID: 3987777 [TBL] [Abstract][Full Text] [Related]
28. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Herman TS; Einhorn LH; Jones SE; Nagy C; Chester AB; Dean JC; Furnas B; Williams SD; Leigh SA; Dorr RT; Moon TE N Engl J Med; 1979 Jun; 300(23):1295-7. PubMed ID: 375088 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Jain AK; Ryan JR; McMahon FG; Smith G J Clin Pharmacol; 1981; 21(S1):320S-326S. PubMed ID: 7028791 [TBL] [Abstract][Full Text] [Related]
30. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. Penta JS; Poster DS; Bruno S; Macdonald JS J Clin Pharmacol; 1981; 21(S1):11S-22S. PubMed ID: 6271815 [TBL] [Abstract][Full Text] [Related]
31. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459 [TBL] [Abstract][Full Text] [Related]
32. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M; Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301 [TBL] [Abstract][Full Text] [Related]
34. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center. Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405 [TBL] [Abstract][Full Text] [Related]
35. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926 [TBL] [Abstract][Full Text] [Related]
36. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [TBL] [Abstract][Full Text] [Related]
37. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy. Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492 [TBL] [Abstract][Full Text] [Related]
38. Oral levonantradol in the control of cancer chemotherapy-induced emesis. Welsh J; Stuart F; Sangster G; Milstead R; Kaye S; Cash H; Charlton D; Calman K Cancer Chemother Pharmacol; 1983; 11(1):66-7. PubMed ID: 6684000 [TBL] [Abstract][Full Text] [Related]
39. Comparative trial of the antiemetic effects of THC and haloperidol. Neidhart JA; Gagen MM; Wilson HE; Young DC J Clin Pharmacol; 1981; 21(S1):38S-42S. PubMed ID: 6271838 [TBL] [Abstract][Full Text] [Related]
40. [Metoclopramide, methylprednisolone and flunitrazepam in cytostatic-induced vomiting]. Joss R; Rohrbach D; Pirovino M; Bischoff A; Kiser J; Brunner K Schweiz Med Wochenschr; 1987 Dec; 117(52):2113-7. PubMed ID: 3433092 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]